Replies to post #124533 on Biotech Values

[mcbio]

It seems the timeline mirrors HALO's even though HALO is in phase 2. I think by the end of year, LLY and/or SNY will probably pick one of the two. I doubt NVO would be interested because they have their own ultra fast insulin program in phase 1.

Two players and two potential partners/acquirers. I'll take those odds, especially with BIOD at about a $40M market cap and enough cash to get them to early 2013. The current market cap is barely above their cash level after their recent raise given the carnage to the stock. Any comments on the risk-reward here? There are no sure things, of course, but I like the risk-reward here. After seeing the stock get crushed in early trading, I managed to come up with enough cash to increase my position by about a third.

[mcbio]

BIOD @ Wedbush (8/16/11)

Regarding the insulin analogs that BIOD is working on, BIOD tested almost 100 different formulations applying their proprietary technology to a major pharma's insulin analog before deciding on 10 to be evaluated further in a diabetic swine model. Of these 10, BIOD believes it has 3 that are potential candidate formulations to move forward into trials (they showed slides with the presentation showing the PK/PD benefit of their version of the analog compared to the analog alone). Discussions are underway with the potential pharma partner and they expect to have a decision in 4Q this year of the analogs and/or RHI (BIOD-105 and BIOD-107) that will move forward (and presumably whether or not they will be doing that alone or in conjunction with the potential big pharma partner).